Leerink Partnrs Issues Optimistic Estimate for ACAD Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Leerink Partnrs raised their Q4 2025 earnings estimates for ACADIA Pharmaceuticals in a report issued on Wednesday, November 5th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will earn $0.11 per share for the quarter, up from their previous estimate of $0.09. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2026 earnings at $0.60 EPS, FY2027 earnings at $0.85 EPS, FY2028 earnings at $1.15 EPS and FY2029 earnings at $0.95 EPS.

ACAD has been the topic of a number of other research reports. TD Cowen lifted their price target on shares of ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, September 11th. UBS Group increased their price target on ACADIA Pharmaceuticals from $36.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday, September 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, October 14th. Royal Bank Of Canada cut their price target on shares of ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Cowen reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.94.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock traded up $0.16 on Friday, hitting $21.81. The stock had a trading volume of 147,609 shares, compared to its average volume of 2,152,113. The stock has a 50 day moving average of $22.69 and a 200 day moving average of $21.84. ACADIA Pharmaceuticals has a twelve month low of $13.40 and a twelve month high of $26.65. The firm has a market capitalization of $3.68 billion, a P/E ratio of 16.37, a PEG ratio of 7.90 and a beta of 0.80.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.28. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The business had revenue of $278.63 million for the quarter, compared to analyst estimates of $276.52 million. During the same quarter in the previous year, the company posted $0.20 EPS. ACADIA Pharmaceuticals’s quarterly revenue was up 11.3% compared to the same quarter last year. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Trading of ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ACAD. Maryland State Retirement & Pension System grew its stake in ACADIA Pharmaceuticals by 1.3% during the second quarter. Maryland State Retirement & Pension System now owns 36,397 shares of the biopharmaceutical company’s stock valued at $785,000 after acquiring an additional 476 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in ACADIA Pharmaceuticals by 11.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 534 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of ACADIA Pharmaceuticals by 0.7% in the 2nd quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company’s stock valued at $1,964,000 after acquiring an additional 626 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of ACADIA Pharmaceuticals by 25.8% during the third quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 690 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in ACADIA Pharmaceuticals by 113.0% during the third quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 756 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors.

Insider Activity at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 22,000 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $25.18, for a total value of $553,960.00. Following the transaction, the executive vice president owned 40,130 shares in the company, valued at approximately $1,010,473.40. This represents a 35.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elizabeth A. Garofalo sold 1,600 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total transaction of $41,568.00. Following the transaction, the director owned 25,382 shares of the company’s stock, valued at $659,424.36. This represents a 5.93% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 27,098 shares of company stock worth $678,256. 26.50% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.